329 related articles for article (PubMed ID: 31142371)
1. Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status.
Chao MW; Chang LH; Tu HJ; Chang CD; Lai MJ; Chen YY; Liou JP; Teng CM; Pan SL
Clin Epigenetics; 2019 May; 11(1):85. PubMed ID: 31142371
[TBL] [Abstract][Full Text] [Related]
2. Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo.
Chen CH; Chen MC; Wang JC; Tsai AC; Chen CS; Liou JP; Pan SL; Teng CM
Clin Cancer Res; 2014 Mar; 20(5):1274-1287. PubMed ID: 24520095
[TBL] [Abstract][Full Text] [Related]
3. The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells.
Chen MC; Chen CH; Wang JC; Tsai AC; Liou JP; Pan SL; Teng CM
Cell Death Dis; 2013 Sep; 4(9):e810. PubMed ID: 24052078
[TBL] [Abstract][Full Text] [Related]
4. Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo.
Huang HL; Peng CY; Lai MJ; Chen CH; Lee HY; Wang JC; Liou JP; Pan SL; Teng CM
Oncotarget; 2015 Mar; 6(7):4976-91. PubMed ID: 25669976
[TBL] [Abstract][Full Text] [Related]
5. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
6. Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression.
Wang Q; Tan R; Zhu X; Zhang Y; Tan Z; Su B; Li Y
Oncotarget; 2016 Mar; 7(9):10064-72. PubMed ID: 26848526
[TBL] [Abstract][Full Text] [Related]
7. Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma.
Lin WC; Hsu FS; Kuo KL; Liu SH; Shun CT; Shi CS; Chang HC; Tsai YC; Lin MC; Wu JT; Kuo Y; Chow PM; Liao SM; Yang SP; Hong JY; Huang KH
J Mol Med (Berl); 2018 Dec; 96(12):1307-1318. PubMed ID: 30288546
[TBL] [Abstract][Full Text] [Related]
8. Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer.
Lindberg JM; Newhook TE; Adair SJ; Walters DM; Kim AJ; Stelow EB; Parsons JT; Bauer TW
Neoplasia; 2014 Jul; 16(7):562-71. PubMed ID: 25117978
[TBL] [Abstract][Full Text] [Related]
9. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
10. HDAC Inhibition Enhances the
Faião-Flores F; Emmons MF; Durante MA; Kinose F; Saha B; Fang B; Koomen JM; Chellappan SP; Maria-Engler SS; Rix U; Licht JD; Harbour JW; Smalley KSM
Clin Cancer Res; 2019 Sep; 25(18):5686-5701. PubMed ID: 31227503
[TBL] [Abstract][Full Text] [Related]
11. Targeted elimination of senescent Ras-transformed cells by suppression of MEK/ERK pathway.
Kochetkova EY; Blinova GI; Bystrova OA; Martynova MG; Pospelov VA; Pospelova TV
Aging (Albany NY); 2017 Nov; 9(11):2352-2375. PubMed ID: 29140794
[TBL] [Abstract][Full Text] [Related]
12. A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells.
Ischenko I; Petrenko O; Hayman MJ
Oncotarget; 2015 Jun; 6(18):15814-27. PubMed ID: 26158412
[TBL] [Abstract][Full Text] [Related]
13. Impairment of K-Ras signaling networks and increased efficacy of epidermal growth factor receptor inhibitors by a novel synthetic miR-143.
Akao Y; Kumazaki M; Shinohara H; Sugito N; Kuranaga Y; Tsujino T; Yoshikawa Y; Kitade Y
Cancer Sci; 2018 May; 109(5):1455-1467. PubMed ID: 29498789
[TBL] [Abstract][Full Text] [Related]
14. Synergistic antitumor effects of the combined treatment with an HDAC6 inhibitor and a COX-2 inhibitor through activation of PTEN.
Zhang G; Gan YH
Oncol Rep; 2017 Nov; 38(5):2657-2666. PubMed ID: 29048666
[TBL] [Abstract][Full Text] [Related]
15. Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.
Morelli MP; Tentler JJ; Kulikowski GN; Tan AC; Bradshaw-Pierce EL; Pitts TM; Brown AM; Nallapareddy S; Arcaroli JJ; Serkova NJ; Hidalgo M; Ciardiello F; Eckhardt SG
Clin Cancer Res; 2012 Feb; 18(4):1051-62. PubMed ID: 22173548
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitor trichostatin A enhances anti-tumor effects of docetaxel or erlotinib in A549 cell line.
Zhang QC; Jiang SJ; Zhang S; Ma XB
Asian Pac J Cancer Prev; 2012; 13(7):3471-6. PubMed ID: 22994780
[TBL] [Abstract][Full Text] [Related]
17. ERK inhibition enhances TSA-induced gastric cancer cell apoptosis via NF-κB-dependent and Notch-independent mechanism.
Yao J; Qian CJ; Ye B; Zhang X; Liang Y
Life Sci; 2012 Sep; 91(5-6):186-93. PubMed ID: 22781708
[TBL] [Abstract][Full Text] [Related]
18. Targeting pancreatic cancer cells by a novel hydroxamate-based histone deacetylase (HDAC) inhibitor ST-3595.
Minjie S; Defei H; Zhimin H; Weiding W; Yuhua Z
Tumour Biol; 2015 Nov; 36(11):9015-22. PubMed ID: 26084607
[TBL] [Abstract][Full Text] [Related]
19. Histone Deacetylase Inhibitor, Trichostatin A, Synergistically Enhances Paclitaxel-Induced Cytotoxicity in Urothelial Carcinoma Cells by Suppressing the ERK Pathway.
Hsu FS; Wu JT; Lin JY; Yang SP; Kuo KL; Lin WC; Shi CS; Chow PM; Liao SM; Pan CI; Hong JY; Chang HC; Huang KH
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30866433
[TBL] [Abstract][Full Text] [Related]
20. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.
Diep CH; Munoz RM; Choudhary A; Von Hoff DD; Han H
Clin Cancer Res; 2011 May; 17(9):2744-56. PubMed ID: 21385921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
